Highest-materiality recent filing
Pro-Dex Q3 revenue record $19.9M; net income up to $3.9M on one-time gain
Q3 net sales record $19.9M, up 15% YoY; driven by $4.7M increase in largest customer's next-gen handpiece.
Pro-Dex acquires Advanced Precision Machining for $8.65M; finances with UMB term loan
Total purchase price ~$8.65M: $6.65M cash at closing (funded by UMB Term Note D) + $2M subordinated note (8% interest, 63 months).
Pro-Dex Q2 sales up 11% to $18.7M; net income $0.66/share; eyes acquisition of supplier
Net sales $18.7M (+11% YoY) driven by $7.3M in next-gen orthopedic handpiece shipments offset by legacy declines.
Pro-Dex extends largest customer contract through 2028, grants CEO $225K bonus
Executed three-year contract amendment with largest customer, extending through Dec 31, 2028.
Compensation committee granted 1,000 restricted shares to CFO Alisha K. Charlton, vesting over five years.
Pro-Dex Q1 FY2026: sales +24% to $18.5M, EPS $1.40 incl. $3.3M unrealized gains
Net sales rose 24% YoY to $18.5M driven by resumed next-generation handpiece production for largest customer.
Full-year net sales $66.6M (+24% YoY), operating income $10.7M (+49%), net income $9.0M ($2.67 diluted EPS) vs $2.1M ($0.60).
Pro-Dex Q3 net income $3.3M ($0.98/share), sales up 22% to $17.4M
Net sales rose 22% to $17.4M driven by $6.2M of next-gen orthopedic handpiece shipments.
Pro-Dex increases revolving credit line from $7M to $11M with UMB Bank
Revolving credit line raised to $11M (from $7M); $5M drawn and outstanding as of April 8, 2025.
Pro-Dex Q2 net sales up 33% to $16.8M; EPS $0.61 vs $0.14
Q2 net sales $16.8M (+33% YoY) driven by $3.1M shipment of next-gen orthopedic handpiece for largest customer.
Pro-Dex Q1 net sales up 25% to $14.9M; net income $2.5M vs loss prior year
Net sales $14.9M (+25% YoY); gross margin 35% (+4pp); operating income $3.0M (+64%).
Q4 net sales $15.0M (+41% YoY); operating income $2.4M (+46%); diluted EPS $0.46 vs $0.42.
Pro-Dex Q3 revenue up 9% to $14.3M; net income falls to $0.19 EPS on investment losses
Net sales $14.3M (+9% YoY); operating income $2.2M (+7%) driven by medical device revenue.
Net sales increased 12% to $12.6M vs $11.3M a year ago; repair revenue from orthopedic surgical handpiece drove growth.
Net loss of $615k ($0.17 diluted) vs net income of $1.2M ($0.33) in prior-year quarter.
Pro-Dex Q4 revenue down 16% YoY; full-year net income up 54% on record backlog $41.6M
Q4 net sales fell 16% YoY to $10.6M; net income down $336K to $1.5M ($0.42 diluted EPS) vs $0.49 last year.
Company will restate audited FY2020-2022 and unaudited interim quarters through Mar 2023; prior reports no longer reliable.
Pro-Dex Q3 net sales up 41% to $13.1M, net income $1.3M vs $462K
Net sales $13.1M (+41% YoY), driven by $3.2M repair revenue from enhanced handpiece program.
Pro-Dex Q2 revenue up 11% to $11.3M; net income dips to $879K from $925K
Q2 net sales $11.3M (+11% YoY); net income $879K ($0.24 diluted EPS) vs $925K ($0.25) last year.
Pro-Dex expands credit facilities to $10M, extends maturity to Dec 2024
Revolving line increased from $2M to $7M; maturity extended from Nov 2023 to Dec 29, 2024.
Pro-Dex Q4 revenue up 34% to $12.6M; full-year net income $3.9M
Q4 net sales $12.6M (+34% YoY); net income $1.4M ($0.38/diluted) vs $0.8M ($0.20) in Q4 FY21.
Pro-Dex Q3 net sales down 21% to $9.3M; EPS $0.12 vs $0.54 YoY
Net sales $9.3M, down $2.5M (21%) from $11.7M due to thoracic driver launch completion.
Pro-Dex Q2 net sales up 23% to $10.2M but net income falls to $0.25 EPS from $0.44
Q2 net sales $10.2M (+23% YoY) driven by orthopedic surgical handpiece sales to largest customer.
Pro-Dex Q1 net sales $10.0M (+16% YoY); diluted EPS $0.28 vs $0.29
Net sales $10.0M for Q1 FY2022 ended Sep 30, 2021, up 16% from $8.6M a year ago.
Pro-Dex Q4 revenue falls 15% YoY; full-year sales up 9%
Q4 net sales $9.4M (-15% YoY); net income $0.9M ($0.22 diluted EPS) vs $2.5M ($0.64) prior year.
the Board appointed Angelita (“Angel”) Domingo, age 49, as a director in order to fill the newly created vacancy due to the expansion of the size of the Board, effective as of December 20, 2021.
Max materiality 0.85 · Median 0.57 · Most common event earnings